Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 3/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6183606 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL5156869 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL475744 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL30720983 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL29040317 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL2896922 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL859599 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL28511990 | 0.90 | ABCB1 (0.49) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL4870228 | 0.90 | ABCB1 (0.52) | ABCB1RIPK1GPR119 | |
| SCHEMBL14074143 | 0.90 | ABCB1 (0.52) | ABCB1RIPK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| CN-110099898-B | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-3700934-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| US-9452990-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| CN-105916500-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 欧洲筛选有限公司 | 2016-08-31 | — | — | CN | disclosed |
| EP-2864322-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1663975-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| WO-2005028440-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| CN-1391473-A | VLA-4 inhibitor compounds | DAIICHI SEIYAKU CO (JP) | 2003-01-15 | — | — | CN | disclosed |
| US-5610144-A | CHOLECYSTOKININ OR GASTRIN ANTAGONISTS; NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS | RHONE-POULENC RORER S.A. (FR) | 1997-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | FFAR2 2512/4885ABCB1 1091/4885RIPK1 2088/4885 |
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | FFAR2 733/4885ABCB1 1901/4885RIPK1 3871/4885 |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | CFB, CFH, TFPI | FFAR2 793/4885ABCB1 2671/4885RIPK1 2402/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | FFAR2 4001/4885ABCB1 129/4885RIPK1 4414/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | FFAR2 766/4885ABCB1 2028/4885RIPK1 4049/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | FFAR2 2694/4885ABCB1 965/4885RIPK1 2190/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | FFAR2 4001/4885ABCB1 129/4885RIPK1 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.